Clinical trials: sponsored by UNICANCER
Metastatic Invasive Breast Cancer
Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.
Rationale: In patients with metastatic breast cancer, fragments of tumor DNA called "circulating tumor DNA" or "ctDNA" can be detected in the blood.
- Trial name
- TAILORswitch (NCT07717450)
- Testing
- Tumor assessment, Completion of Quality-of-life questionnaires, ECG
- Volunteers
- 370 people
- Sponsor
- UNICANCER
Ewing Sarcomas, Chondrosarcomas
A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas
INDICATION: Metastatic bone sarcomas: conventional high grade osteosarcoma, Ewing sarcoma of bone, intermediate or high-grade chondrosarcomas and chordomas and either bone or soft tissue metastatic CIC-rearranged sarcomas
- Conditions
- Ewing Sarcomas, Chondrosarcomas, Osteosarcomas, Chondroma
- Trial name
- REGOBONE (NCT02389244)
- Testing
- Regorafenib
- Where
- 19 sites in France
- Volunteers
- 163 people
- Sponsor
- UNICANCER
Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Cancers
SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer
Oropharyngeal cancer (OPC) is the most common type of head and neck cancer. The current standard treatment for this cancer is radiotherapy (RT) of the tumour and lymph nodes of both sides of the neck, combined with concurrent…
- Conditions
- Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Cancers, Oropharyngeal Carcinoma, Head and Neck
- Trial name
- SELECT-FR (NCT07241273)
- Testing
- Lymphatic mapping with SPECT-CT, Bilateral neck radiotherapy, Ipsilateral neck radiotherapy & SPECT-CT guided contralateral neck radiotherapy
- Where
- 12 sites in France
- Volunteers
- 128 people
- Sponsor
- UNICANCER
Metastatic Breast Cancer, HER2-positive Breast Cancer
Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.
Heroes is a multicentre, national, non-randomized, open-label, phase 2 study. The goal of this clinical trial is to evaluate the feasibility of therapeutic de-escalation in HER2-positive metastatic breast cancer with disease…
- Trial name
- HEROES (NCT06450314)
- Testing
- Discontinuation of the anti-HER2 maintenance therapy, Monitoring with signatera test
- Where
- France
- Volunteers
- 170 people
- Sponsor
- UNICANCER
Cutaneous Melanoma, Stage III, Mucosal Melanoma
Neo-adjuvant Immunotherapy in Patients With Localized Melanoma
The success of anti-PD-1 and anti-CTLA-4 therapies has initiated a paradigm shift in oncology, with drugs now targeting the immune system rather than cancer cells to stimulate the antitumor immune response.
- Trial name
- NEOREM-NEO-1 (NCT07230613)
- Testing
- Ipilimumab (YervoyTM, 50 mg/10 mL solution), Nivolumab (OpdivoTM, 40 mg/4mL solution)
- Where
- 6 sites in France
- Volunteers
- 50 people
- Sponsor
- UNICANCER
Breast Cancer
Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk
Hormone therapy is recommended for five years in all patients with hormone receptor-positive breast cancer, but there is no consensus on its duration in low-risk tumours and especially in postmenopausal women.
- Trial name
- LESS (NCT05297617)
- Testing
- Anti-aromatase inhibitor
- Where
- 2 sites in France
- Volunteers
- 696 people
- Sponsor
- UNICANCER
Breast Cancer
Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment
The purpose of the study is to evaluate the benefit of adjuvant chemotherapy on overall survival for elderly patients with breast cancer, in a sub group with a high risk of relapse according to Genomic Grade test.
- Trial name
- ASTER 70s (NCT01564056)
- Testing
- HORMONOTHERAPY, CHEMOTHERAPY then HORMONOTHERAPY
- Where
- 84 sites in Belgium, France
- Volunteers
- 1,989 people
- Sponsor
- UNICANCER
Lung Cancer Metastatic, Renal Cell Carcinoma
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
Immunotherapy (IO), such as treatment with anti-PD-1, PD-L1, or CTLA-4 inhibitors, is a rapidly expanding treatment for multiple metastatic cancers with improved survival for certain cancers.
- Conditions
- Lung Cancer Metastatic, Renal Cell Carcinoma, Head and Neck Cancer, Triple Negative Breast Cancer
- Trial name
- MOIO (NCT05078047)
- Testing
- Reduced dose intensity of IO
- Where
- 33 sites in France
- Volunteers
- 646 people
- Sponsor
- UNICANCER
Colorectal Cancer
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma
This study is being done to answer the main question of: Do patients with colorectal cancer that cannot be removed by surgery, that is treated with two new immunotherapy drugs, botensilimab and balstilimab, live longer? Other…
- Trial name
- BATTMAN (NCT07152821)
- Testing
- Best Supportive Care, Balstilimab, Botensilimab
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- Canadian Cancer Trials Group
Adenoid Cystic Carcinoma of the Salivary Gland, Recurrence
Study to Evaluate the Efficacy of Zanzalintinib in the Treatment of Relapsed or Metastatic Adenoid Cystic Carcinomas of the Head and Neck
Adenoid cystic carcinomas are rare cancers of the salivary glands. These cancers are treated with curative surgery, often followed by radiation therapy.
- Conditions
- Adenoid Cystic Carcinoma of the Salivary Gland, Recurrence, Metastatic Disease
- Trial name
- ZANACC (NCT07682675)
- Testing
- Zanzalintinib
- Where
- 2 sites in France
- Volunteers
- 51 people
- Sponsor
- UNICANCER
Germ Cell Tumor, Teratoma
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
This randomized phase III trial studies how well standard-dose combination chemotherapy works compared to high-dose combination chemotherapy and stem cell transplant in treating patients with germ cell tumors that have returned…
- Conditions
- Germ Cell Tumor, Teratoma, Choriocarcinoma, Germinoma
- Trial name
- NCT02375204
- Testing
- paclitaxel, ifosfamide, cisplatin
- Where
- 125 sites in United States, Australia and 10 more
- Volunteers
- 420 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Malignant Melanoma, BRAF V600 Mutation
Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis
This study evaluates the addition of stereotactic radiosurgery (SRS) to the combination of binimetinib + encorafenib + pembrolizumab in the treatment of BRAFⱽ⁶⁰⁰ mutation-positive melanoma with brain metastases (MBM).
- Conditions
- Malignant Melanoma, BRAF V600 Mutation, Brain Metastases
- Trial name
- BEPCOME-MB (NCT04074096)
- Testing
- Stereotaxic radiosurgery (SRS), Binimetinib Oral Tablet, Encorafenib Oral Capsule
- Where
- 21 sites in France
- Volunteers
- 10 people
- Sponsor
- UNICANCER
Ovarian Cancer
Evolution of the Therapeutic Care in Ovarian Cancer From 2011
The ESME Ovarian Cancer database is a multi-center real life database using a retrospective data collection process in 18 French Comprehensive Cancer Center (FCCC) over 20 sites).
- Trial name
- ESME OC (NCT03275298)
- Where
- 20 sites in France
- Volunteers
- 13,331 people
- Sponsor
- UNICANCER
Metastatic Breast Cancer
Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008
The Epidemiological Strategy and Medical Economic (ESME) Breast cancer Database is a multicenter real life database using a retrospective data collection process across 18 French comprehensive cancer centers (FCCC) spread over 20…
- Trial name
- ESME-MBC (NCT03275311)
- Where
- 20 sites in France
- Volunteers
- 42,000 people
- Sponsor
- UNICANCER
Lung Cancer
Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)
This database compiles data from existing data available from patient's electronic medical records (EMR) at the 38 participating hospitals (20 French comprehensive cancer centers and 18 public hospitals).
- Trial name
- NCT03848052
- Where
- 21 sites in France
- Volunteers
- 75,000 people
- Sponsor
- UNICANCER
Head and Neck Squamous Cell Carcinoma, Anal Cancer
Blood Biomarkers Based Screening for HPV-driven OPC
The objective of our study is to demonstrate that it is possible to detect and treat human papilloma virus (HPV)-related oropharyngeal cancers (OPC) early using simple blood tests.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Anal Cancer, Human Papilloma Virus
- Trial name
- SCREEN-HPV (NCT06528353)
- Testing
- HPV16-E6 serology and HPV ctDNA
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- UNICANCER
Breast Cancer
Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib
The advent of CDK4/6 inhibitors (drugs designed to block the action of CDK4/6 proteins, which play a key role in cell proliferation) has improved treatment prospects for patients with metastatic breast cancer whose tumour cells…
- Trial name
- NoLEEta (NCT07237256)
- Testing
- Chemotherapy followed by endocrine therapy and ribociclib treatment, De-escalation
- Where
- 138 sites in France, Germany and 3 more
- Volunteers
- 3,902 people
- Sponsor
- UNICANCER
Colorectal Adenocarcinoma Metastatic in the Liver, Colorectal Cancer
Liver-directed Chemotherapy After Surgery of Liver Metastases of Colorectal Cancer in Patients With High Risk of Recurrence of Their Disease
At the time of diagnosis, 25% of patients with colorectal cancer present with liver metastasis (CRLM). Among patients with localized colorectal cancer (Stages I-III), 50% to 70% will develop liver metastases during the course of…
- Trial name
- PACHA-02 (NCT07284394)
- Testing
- Arterial catheter infusion chemotherapy, IV Chemotherapy (Regimen 1)
- Volunteers
- 272 people
- Sponsor
- UNICANCER
Breast Cancer Stage IV, Radiotherapy
Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients
Approximately 3.5% to 6% of newly diagnosed breast cancer patients are stage IV metastatic. De novo metastatic breast cancer accounts for 20% to 25% of these cases.
- Conditions
- Breast Cancer Stage IV, Radiotherapy, Surgery
- Trial name
- PALATINE (NCT03870919)
- Testing
- Palbociclib, locoregional treatment
- Where
- 26 sites in France
- Volunteers
- 200 people
- Sponsor
- UNICANCER
Ovarian Epithelial Cancer Recurrent
Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment
CHIPOR hypothesis is that the adjunction of platinum HIPEC in first relapsed epithelial ovarian cancer is able to improve the median Overall Survival (OS) by 12 months.
- Trial name
- CHIPOR (NCT01376752)
- Testing
- Maximal cytoreductive surgery, HIPEC
- Where
- 33 sites in Belgium, France and 1 more
- Volunteers
- 415 people
- Sponsor
- UNICANCER